MediStem, Inc. (Formerly known as Medistem Laboratories, Inc.) Appoints John Salvador J.D. Chief Operating Officer

SAN DIEGO, CA--(Marketwired - July 10, 2013) - Medistem, Inc. (PINKSHEETS: MEDS), today announced a key addition to its executive team with the appointment of John Salvador, J.D. as Chief Operating Officer. With a proven track record of successfully guiding companies through strategic transformations, Mr. Salvador will compliment the existing management team as the Company returns to a fully reporting status with the Securities and Exchange Commission.

In addition, Mr. Salvador will oversee the Company's institutional fund raising efforts, investor relations, and legal affairs. Reporting to the Company CEO, Alan J. Lewis, Ph.D., Mr. Salvador will serve on the company's executive management team.

With over 15 years of experience, Mr. Salvador has successfully managed operations, private and public offerings, strategic transformations, and mergers and acquisitions and has been instrumental in raising over $350 million in several private and public offerings. Mr. Salvador holds a Juris Doctor from Boston University. Prior to joining Medistem, Mr. Salvador had similar responsibilities at Aethlon Medical, a medical device company with a recent FDA clearance. He also has executive level experience in the electronic gaming and financial industries,

"We are delighted to have John join our management team. His experience advising public companies will be instrumental in raising our profile with the investment community," said Dr. Lewis, "John's expertise will be instrumental in executing our strategy to uplist to NASDAQ."

"Medistem represents a unique opportunity to continue to pursue my passion for innovative therapies addressing unmet medical needs," said Mr. Salvador. "Medistem's lead product, the Endometrial Regenerative Cell (ERC) is an FDA cleared therapeutic that addresses the multibillion cardiovascular disease market.

About Medistem, Inc.

Medistem, Inc., is focused on the development of the Endometrial Regenerative Cell (ERC), a universal donor adult stem cell product. ERCs possess specialized abilities to stimulate new blood vessel growth and can differentiate into lung, liver, heart, brain, bone, cartilage, fat and pancreatic tissue. These unique properties have applications for treatment of critical limb ischemia (CLI), congestive heart failure (CHF), neurodegenerative diseases, liver failure, kidney failure, and diabetes. ERCs have been cleared by the FDA to begin studies in the United States. In January 2012, we announced the initiation of our RECOVER-ERC (Non-Revascularizable IschEmic Cardiomyopathy treated with Retrograde COronary Sinus Venous DElivery of Cell TheRapy) Phase II clinical trial. This trial is being conducted at the Bakulev Scientific Center for Cardiovascular Surgery, Moscow, Russia. The trial is a 60 patient double blind placebo controlled study evaluating safety and efficacy of ERCs in end stage CHF patients.

Certain statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Medistem, Inc. These can be identified by the use of forward-looking words, such as "believes", "expects", "may", "intends", "anticipates", "plans", "estimates", or any other analogous or similar expressions intended to identify forward-looking statements. These forward-looking statements and estimates as to future performance, estimates, and other statements contained herein regarding matters that are not historical facts, are only predictions and actual events or results may differ materially. We cannot assure or guarantee that any future results described in this presentation will be achieved, and actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.